Johnson & Johnson (JNJ.N) announced on Monday its intention to purchase the biotechnology firm Firefly Bio for $1 billion in cash, aiming to broaden its range of cancer medications.
Firefly’s system, named Firelink, employs antibodies to deliver a protein-degrading medication straight to malignant cells. J&J suggests this method might enable more precise tumor treatment, causing less harm to healthy tissues compared to current therapies.
This technology specifically targets tumors exhibiting a KRAS mutation, a strategic step that the corporation indicated further reinforces J&J’s concentration on oncology and its objective of creating specialized treatments for the most prevalent and difficult solid tumors that have significant unmet medical requirements.
“KRAS has historically been viewed as an ‘inaccessible’ target, and individuals diagnosed with KRAS-related cancers still face restricted therapeutic choices, with their lifespan measured in months rather than years,” stated John Reed, the executive vice president of J&J’s innovative medicine and research division.
This acquisition is anticipated to finalize by the close of the current year.
Source: Reuters